In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
Since September 2012, the marketing licence in the UK has been held by Flynn Pharma Ltd, of Dublin, Ireland , and the product, although identical, has been called Phenytoin Sodium xx mg Flynn Hard Capsules. (The xx mg in the name refers to the strength—for example 'Phenytoin sodium 25 mg Flynn Hard Capsules').  The capsules are still made by Pfizer 's Goedecke subsidiary's plant in Freiburg , Germany and they still have Epanutin printed on them.  After Pfizer's sale of the UK marketing licence to Flynn Pharma, the price of a 28-pack of 25 mg phenytoin sodium capsules marked Epanutin rose from 66p (about $) to £ (about $). Capsules of other strengths also went up in price by the same factor—2384%,  costing the UK's National Health Service an extra £43 million (about $ million) a year.  The companies were referred to the Competition and Markets Authority who found that they had exploited their dominant position in the market to charge “excessive and unfair” prices.